Teclistamab 是一种人源的 BCMA 和 CD3 双特异性抗体，可识别靶细胞上的 BCMA 和 T 细胞上的 CD3，诱导 T 细胞介导的细胞毒性，导致 T 细胞的活化和随后的靶细胞裂解。Teclistamab 可用于多发性骨髓瘤等相关疾病研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-CD3 & BCMA Reference Antibody (Teclistamab) is 143.38 kDa.

Anti-CD3 & BCMA Reference Antibody (Teclistamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.

The purity of Anti-CD3 & BCMA Reference Antibody (Teclistamab) is more than 97.30%, determined by SEC-HPLC.

Teclistamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Teclistamab bound to huBCMA-ECD-His , and the EC50 was 0.106 nM.

Teclistamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Teclistamab bound to huBCMA-HEK293 cells, and the EC50 was 2.421 nM.

Teclistamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Teclistamab bound to huCD3e-jurkat cells, and the EC50 was 1.774 nM.

Co-incubation of Teclistamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Teclistamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.279 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.